Skip to content
Screener

EyePoint, Inc. EYPT Cash & Equivalents

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$6.89B-14.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$666.7M+90.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$169.53M+22.1%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$72.49M-45.7%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.11B+51.9%
Enterprise value$1.02B+49.6%
P/S396.6×+383×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037

FAQ

What is EyePoint, Inc.'s cash & equivalents?
EyePoint, Inc. (EYPT) reported cash & equivalents of $110.46M in Q2 2026.
How has EyePoint, Inc.'s cash & equivalents changed year-over-year?
EyePoint, Inc.'s cash & equivalents increased by 55.3% year-over-year, from $71.14M to $110.46M.
What is the long-term trend for EyePoint, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), EyePoint, Inc.'s cash & equivalents has grown at a 17.8% compound annual growth rate (CAGR), from $44.91M to $101.82M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about EyePoint, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude